Clinical research associates (CRAs) spend less than half of their time conducting ‘on site’ monitoring with training, travel and admin taking up the majority of their time according to new research
Quintiles has invested £3m ($4.6m) in a new UK-based biomarker R&D company in a continuation of its efforts to build in the field of personalised medicines.
A prior relationship rather than price was the most significant factor in helping Icon win its strategic deal with Shire according to an analyst who says such a trend is good for the sector.
ACRO says latest draft rules on trials in India – which would see ethics committees take sole responsibility for determining SAE cause and compensation - are a backwards step that would make high quality research impossible.
GSK CEO Andrew Witty has been knighted in the Queen's New Year Honours list in recognition of his services to the UK economy and pharmaceutical industry.
Manufacturing operations at Shasun Pharma’s plant in Cuddalore, Tamil Nadu are still suspended days after Southern India was battered by a cyclonic storm.
DSM Biologics will work with the Australian Institute for Bioengineering and Nanotechnology (AIBN) on the commercialisation of development-stage biologics projects.
New Asian CRO Alliance (ACA) can offer faster and better decision making than multinational CROs says Semler Research Centre's clinical development VP.
GE Healthcare and M+W Group aim to capture a share of the rapidly expanding global biologics market with a new plant and manufacturing tech partnership.
Ireland-based CRO Icon says acquisition of Chinese trial firm BeijingWits Medical Consulting will boost capabilities in the country and help meet growing demand from global clients.
In September Outsourcing-pharma held Patient Recruitment Outsourcing (PRO) in Boston, bringing together the movers and shakers in the recruitment sector. Robert Loll, vice president of business development, shares his thoughts on the event with a particular...
Sponsor and CRO perceptions of the quality of outsourced service provision differ markedly according to a study by consulting and survey research organisation, the Avoca Group.
Samsung will set up a $300m biosimilars development JV with Massachusetts, US-based Biogen Idec, building on the partnership it forged with CRO Quintiles earlier this year.
Cincinnati, US-based Schulman Associates Institutional Review Board (IRB) has bought Florida counterpart Independent Investigational Review Board (IIR) to broaden its offering for Pharmas and CROs.
